169 related articles for article (PubMed ID: 15242421)
1. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients.
Wada-Isoe K; Wakutani Y; Urakami K; Nakashima K
Acta Neurol Scand; 2004 Aug; 110(2):124-7. PubMed ID: 15242421
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
[TBL] [Abstract][Full Text] [Related]
3. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia.
Leszek J; Małyszczak K; Janicka B; Kiejna A; Wiak A
Med Sci Monit; 2003 Nov; 9(11):CR484-8. PubMed ID: 14586274
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
Hu Y; He S; Wang J
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
[TBL] [Abstract][Full Text] [Related]
5. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
Rentzos M; Paraskevas GP; Kapaki E; Nikolaou C; Zoga M; Rombos A; Tsoutsou A; Vassilopoulos D D
J Neurol Sci; 2006 Nov; 249(2):110-4. PubMed ID: 16843497
[TBL] [Abstract][Full Text] [Related]
7. [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease].
Schonknecht P; Pantel J; Werle E; Hartmann T; Essig M; Baudendistel K; Beyreuther K; Schroder J
Fortschr Neurol Psychiatr; 2000 Oct; 68(10):439-46. PubMed ID: 11103680
[TBL] [Abstract][Full Text] [Related]
8. Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.
Jia JP; Jia JM; Zhou WD; Xu M; Chu CB; Yan X; Sun YX
Chin Med J (Engl); 2004 Aug; 117(8):1161-4. PubMed ID: 15361288
[TBL] [Abstract][Full Text] [Related]
9. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
Nishimura T; Takeda M; Nakamura Y; Yosbida Y; Arai H; Sasaki H; Shouji M; Hirai S; Khise K; Tanaka K; Hamamoto M; Yamamoto H; Matsubayashi T; Urakami K; Adachi Y; Nakashima K; Toji H; Nakamura S; Yoshida H
Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):227-35. PubMed ID: 9646285
[TBL] [Abstract][Full Text] [Related]
10. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases.
Brettschneider J; Widl K; Ehrenreich H; Riepe M; Tumani H
Neurosci Lett; 2006 Sep; 404(3):347-51. PubMed ID: 16815630
[TBL] [Abstract][Full Text] [Related]
13. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia.
Di Rosa M; Dell'Ombra N; Zambito AM; Malaguarnera M; Nicoletti F; Malaguarnera L
Eur J Neurosci; 2006 May; 23(10):2648-56. PubMed ID: 16817867
[TBL] [Abstract][Full Text] [Related]
14. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
15. Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
Bibl M; Esselmann H; Mollenhauer B; Weniger G; Welge V; Liess M; Lewczuk P; Otto M; Schulz JB; Trenkwalder C; Kornhuber J; Wiltfang J
J Neurochem; 2007 Oct; 103(2):467-74. PubMed ID: 17662050
[TBL] [Abstract][Full Text] [Related]
16. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia.
Zuliani G; Ranzini M; Guerra G; Rossi L; Munari MR; Zurlo A; Volpato S; Atti AR; Blè A; Fellin R
J Psychiatr Res; 2007 Oct; 41(8):686-93. PubMed ID: 16600299
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
Engelborghs S; Maertens K; Vloeberghs E; Aerts T; Somers N; Mariën P; De Deyn PP
Neurochem Int; 2006 Mar; 48(4):286-95. PubMed ID: 16434124
[TBL] [Abstract][Full Text] [Related]
18. Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy.
Schmitz M; Hermann P; Oikonomou P; Stoeck K; Ebert E; Poliakova T; Schmidt C; Llorens F; Zafar S; Zerr I
Neurobiol Aging; 2015 Sep; 36(9):2597-606. PubMed ID: 26170132
[TBL] [Abstract][Full Text] [Related]
19. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
Popp J; Bacher M; Kölsch H; Noelker C; Deuster O; Dodel R; Jessen F
J Psychiatr Res; 2009 May; 43(8):749-53. PubMed ID: 19038405
[TBL] [Abstract][Full Text] [Related]
20. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients.
Rota E; Bellone G; Rocca P; Bergamasco B; Emanuelli G; Ferrero P
Neurol Sci; 2006 Apr; 27(1):33-9. PubMed ID: 16688597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
